the gastric cancer study in surgery and pathology. I. Clinical classification . Jpn J Surg 1981 ; 11 : 127 – 139 . 38 Soga J Kobayashi K Saito J . The role of lymphadenectomy in curative surgery for gastric cancer . World J Surg 1979
Search Results
; • support governments in LLMICs to develop sustainable health financing, which covers adequate staffing and medicines for cancer treatment; • support the development of sustainable diagnostic and pathology capacity; • implement training and education
Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes
kidney, hydronephrosis, metanephric tumors (ie, adenoma, stromal tumor, adenofibroma), multicystic kidney disease, polycystic kidney disease, renal hemorrhage, and renal vein thrombosis. Pathology To avoid potential tumor spread from malignant
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead
developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical, surgical, and radiation oncology and pathology, reconstructive surgery, and patient advocacy. This
Oncology Research Program (ORP) and Bristol-Myers Squibb (BMS) are collaborating on the NCCN/BMS Thoracic Pathology Protocol Development Team. This team will be responsible for a study designed to: understand how different assays measure PD-L1 protein
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. Klempner, Jill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, and Lenora A. Pluchino
pathology assessments to establish cTNM and ypTNM stages has never been validated and may not be appropriate. Therefore, new cTNM and ypTNM stage groupings and prognostic information were added to the eighth edition to overcome these issues. New clinical
Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla, and Arun S. Singh
. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease . Hum Mol Genet 1997 ; 6 : 1383 – 1387 . 3 Starink TM Hausman R . The cutaneous pathology of extrafacial lesions in Cowden's disease . J Cutan Pathol 1984 ; 11 : 338
Darren Sigal, Marie Tartar, Marin Xavier, Fei Bao, Patrick Foley, David Luo, Jason Christiansen, Zachary Hornby, Edna Chow Maneval, and Pratik Multani
It is not surprising that the molecular pathogenesis of NETs remains elusive with this degree of clinical heterogeneity. Many investigations into the tumorigenesis of NETs have focused on SI-NETs and PNETs, but their molecular pathology is still
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
neoadjuvant FOLFIRINOX followed by pancreaticoduodenectomy with negative margins and 6 cycles of adjuvant FOLFIRINOX. Surgical pathology revealed ypT3N1Mx (stage IIB) adenocarcinoma. Eight months after completion of adjuvant therapy, PET imaging revealed
M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz
her tumor 3 weeks after discontinuing imatinib. Because of the location of the tumor and involvement of the SMV, a Whipple procedure was required. However, it was believed that the neoadjuvant imatinib made this procedure possible. Pathology revealed a
